Vijaya Diagnostic Centre Ltd Share Price – NSE /  BSE

Healthcare, Small Cap

Vijaya Diagnostic Centre has granted 90,000 ESOPs under the ?VDCL Employee Stock Option Plan 2018?. These options are convertible into 90,000 equity shares of face value Re 1/- each.

According to a regulatory filing, Prasad's resignation will take effect from August 8, 2026, which will be his last working day with the company.

The diagnostic services provider said it places on record its appreciation for the services rendered by Prasad and acknowledged his contributions during his tenure with the company.

No further details regarding his successor were disclosed in the filing.

Vijaya Diagnostic Centre is one of India?s largest integrated diagnostic chains. The company offers comprehensive diagnostic services ranging from basic pathology to high-end radiology.

The company?s consolidated net profit jumped 37.64% to Rs 47.92 crore on 26.62% rise in revenue from operations to Rs 219.37 crore in Q4 FY26 over Q4 FY25.

The scrip shed 0.32% to Rs 1,295 on the BSE.

Powered by Capital Market - Live News

According to the company's regulatory filing, Shah will cease to hold the position on or before July 24, 2026.

The company did not disclose the reason for the resignation in the filing. Further details regarding the appointment of a new CFO are awaited.

The disclosure was made in compliance with regulatory requirements under stock exchange listing norms.

Vijaya Diagnostic Centre is one of India?s largest integrated diagnostic chains. The company offers comprehensive diagnostic services ranging from basic pathology to high-end radiology.

The company?s consolidated net profit jumped 37.64% to Rs 47.92 crore on 26.62% rise in revenue from operations to Rs 219.37 crore in Q4 FY26 over Q4 FY25.

The scrip shed 0.09% to Rs 1305.90 on the BSE.

Powered by Capital Market - Live News

Vijaya Diagnostic Centre announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 200%) , subject to the approval of the shareholders.